Hadassah

Hadassah Researchers Develop Human Embryonic Stem Cell Lines Suitable for Humans

Tuesday, Jun 26 2012

Researchers at the Hadassah University Medical Organization in Jerusalem have produced, for the first time, under Good Manufacturing Practices (GMP) conditions, lines of human embryonic stem cells (hESCs) for transplantation that are free of animal components.

As the researchers explain: "Most of the reported hESC lines worldwide are not ideal for use in clinical trials. They were developed without adherence to Good Manufacturing Practices (GMPs), using animal-derived research-grade reagents, which may infect the cells with animal pathogens. Moreover, many cell lines were derived and cultured on animal feeder cells, which may contaminate the hESCs by nonhuman sialic acid Neu5Gc molecules, which can elicit immune rejection after transplantation."

Human embryonic stem cells can differentiate and mature into any cell type in the human body. This gives them the potential to serve as an infinite source of cells for transplantation to mitigate degenerative diseases such as diabetes, heart failure, and Parkinson's.

The new stem cell lines were produced from six-day-old embryos donated by couples who had completed their in vitro fertilization treatments. After reviewing the ethical procedures involved in the embryo donation and the production of the stem cells, both Israel's Ministry of Health and the United States National Institutes of Health (NIH) found them appropriate and granted ethical approval. The NIH approval allows researchers in the United States to use these new cell lines in studies funded by the federal government.

Prof. Benjamin Reubinoff, Director of the Sidney and Judy Swartz Human Embryonic Stem Cell Research Center, headed the study, which is highlighted in the June 20, 2012 issue of PLoS ONE, an international, peer-reviewed, open-access, online publication of the Public Library of Science. The cell lines have already been provided to two Israeli companies: Cell Cure Neurosciences Ltd.--to develop transplantation treatment for Age-Related Macular Degeneration--and Kadimastem Ltd. for diabetes. Hadasit, Hadassah's technology transfer company, commercialized the new technology by awarding licenses to the two companies and is overseeing the translational process.

The study was partially conducted by the Bereshit Consortium, a group of companies and academic institutions funded by Israel's Ministry of Industry, Trade and Labor to advance the development of stem cell transplantations.

Read the story in The Jerusalem Post here. 

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Mar 22 2019

On World TB Day, March 24, Hadassah Celebrates Its Success Treating TB

Hadassah has been working on reducing the incidence of tuberculosis for nearly 100 years.

READ MORE ›
alt_text

Thursday, Mar 21 2019

Large Multinational Study Reveals Benefits of Dapagliflozin for Treatment of Diabetes

With 450 million adults worldwide suffering from diabetes today and an increase to more than 640 million expected by 2040, the need for a safe and effective treatment is ever more compelling.

READ MORE ›
alt_text

Tuesday, Mar 19 2019

Hadassah Genetic Research Demystifies Causes of Day Blindness in Families

Fifteen years ago, Prof. Dror Sharon joined the Hadassah Medical Organization’s Center for Retinal and Macular Degeneration to study the genetics of eye disease.

READ MORE ›
alt_text

Wednesday, Mar 13 2019

Saving Lives, Changing Lives at Hadassah-Neurim Youth Aliyah Village

Henrietta Szold was the mother of Youth Aliyah. The first young Jews who came on their own in the mid-1930s were fleeing Hitler. Many never saw their parents again, and they called her Ima. She met their boats, welcomed them, and became their staunch advocate in the no-frills pre-state Israel.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More